ASSEMBLY BIOSCIENCES INC (ASMB)
US0453962070 - Common Stock
ASMB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. The financial health of ASMB is average, but there are quite some concerns on its profitability. ASMB does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ASMB has reported negative net income.
ASMB had a positive operating cash flow in the past year.
ASMB had negative earnings in each of the past 5 years.
In the past 5 years ASMB reported 4 times negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -44.75%, ASMB perfoms like the industry average, outperforming 55.12% of the companies in the same industry.
ASMB has a Return On Equity of -148.99%. This is in the lower half of the industry: ASMB underperforms 66.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.75% | ||
| ROE | -148.99% | ||
| ROIC | N/A |
ROA(3y)-68.05%
ROA(5y)-50.96%
ROE(3y)-112.81%
ROE(5y)-80%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ASMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ASMB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ASMB has been reduced compared to 1 year ago.
Compared to 5 years ago, ASMB has less shares outstanding
There is no outstanding debt for ASMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -8.28, we must say that ASMB is in the distress zone and has some risk of bankruptcy.
ASMB's Altman-Z score of -8.28 is on the low side compared to the rest of the industry. ASMB is outperformed by 74.57% of its industry peers.
ASMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | -8.28 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
A Current Ratio of 3.41 indicates that ASMB has no problem at all paying its short term obligations.
ASMB has a Current ratio of 3.41. This is in the lower half of the industry: ASMB underperforms 61.95% of its industry peers.
A Quick Ratio of 3.41 indicates that ASMB has no problem at all paying its short term obligations.
ASMB has a worse Quick ratio (3.41) than 60.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.41 | ||
| Quick Ratio | 3.41 |
3. Growth
3.1 Past
ASMB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -95.57%.
Measured over the past years, ASMB shows a very negative growth in Revenue. The Revenue has been decreasing by -13.51% on average per year.
EPS 1Y (TTM)-95.57%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q61.05%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-55.1%
Revenue growth 5Y-13.51%
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 14.43% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.03%
EPS Next 2Y-8.44%
EPS Next 3Y-7.59%
EPS Next 5Y14.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ASMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASMB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, ASMB is valued cheaper than 99.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.12 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ASMB's earnings are expected to decrease with -7.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.44%
EPS Next 3Y-7.59%
5. Dividend
5.1 Amount
ASMB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ASSEMBLY BIOSCIENCES INC
NASDAQ:ASMB (4/29/2024, 11:31:32 AM)
12.79
+0.14 (+1.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap70.09M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.75% | ||
| ROE | -148.99% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.41 | ||
| Quick Ratio | 3.41 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-95.57%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-11.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3Y-55.1%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y